Chimerix Inc. (NASDAQ:CMRX) shares shot up 2.3% during trading on Monday . The company traded as high as $4.48 and last traded at $4.41, with a volume of 239,714 shares trading hands. The stock had previously closed at $4.31.

A number of brokerages recently commented on CMRX. FBR & Co reaffirmed a “hold” rating on shares of Chimerix in a research report on Sunday, July 17th. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research report on Wednesday, August 10th. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $7.00 price objective on shares of Chimerix in a research report on Tuesday, August 9th. Finally, Piper Jaffray Cos. set a $12.00 price objective on shares of Chimerix and gave the company a “buy” rating in a research report on Thursday, August 18th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Chimerix presently has an average rating of “Hold” and a consensus price target of $15.72.

The firm has a 50 day moving average price of $4.17 and a 200 day moving average price of $4.90. The stock’s market capitalization is $229.91 million.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.12. The company had revenue of $1.80 million for the quarter, compared to analyst estimates of $1.98 million. On average, equities analysts anticipate that Chimerix Inc. will post ($1.78) EPS for the current fiscal year.

In related news, Director Ernest Mario bought 50,000 shares of the company’s stock in a transaction on Friday, June 24th. The shares were purchased at an average cost of $3.70 per share, for a total transaction of $185,000.00. Following the acquisition, the director now owns 381,440 shares of the company’s stock, valued at approximately $1,411,328. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CEO M Michelle Berrey bought 13,188 shares of the company’s stock in a transaction on Friday, June 24th. The shares were bought at an average price of $3.69 per share, for a total transaction of $48,663.72. Following the completion of the acquisition, the chief executive officer now directly owns 258,821 shares in the company, valued at approximately $955,049.49. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Chimerix stock. Jennison Associates LLC increased its stake in Chimerix Inc. (NASDAQ:CMRX) by 67.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,273,779 shares of the biopharmaceutical company’s stock after buying an additional 515,029 shares during the period. Jennison Associates LLC owned 2.76% of Chimerix worth $11,400,000 as of its most recent filing with the SEC.

Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.